Pharmexcil Seeks Industry Input on Kuwait Market Access

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) invites suggestions from Indian pharmaceutical companies for overcoming market access barriers in Kuwait after the formation of the India-Kuwait Joint Working Group (JWG) on Trade and Commerce to facilitate sectoral bilateral collaboration.

Raja Bhanu, Director General of Pharmexcil, stated that the council expects input in detail from member-companies not only about the regulatory but also technical and operational difficulties faced with the Kuwait Drug & Food Control Authority (KDFCA) and Ministry of Health (MoH).

The problems mentioned here range from product registration and renewals to pricing, import permissions, and any other issues. Inputs are being collected to bring industry grievances to officials who can solve them.

A study on the market, commissioned by the Embassy of India in Kuwait, and conducted by MARMORE MENA Intelligence, reveals that there are significant chances for Indian companies in Kuwait's pharmaceuticals field.

Also Read: Renofluthrin Molecule Puts India Ahead in Mosquito Control Tech

The study recommends a need for hi-tech drug formulations, the possibility of forming partnerships in biosimilars, and motivating for the localization of packaging and manufacturing. Kuwait is rolling out several measures to attract innovation in continuous manufacturing, modular factory design, and university-industry partnership.

The Kuwaiti pharmaceutical market showed vibrant development from 2020 till 2024, which was beyond the GCC region. This growth was majorly driven by vaccine-related revenues in the post-pandemic era. Pharmexcil’s Indian exporter engagement is designed to seize these prospects, thus achieving easier market access and encouraging long-term trade relations between India and Kuwait.